The weight loss market sees more ups and downs - <a href="https://www.biospace.com/article/altimmune-joins-weight-loss-race-with-phase-ii-win-stock-jumps-on-news/" target="_blank" rel="noopener noreferer">Altimmune</a> joins the fray and sees a stock jump while <a href="https://www.biospace.com/article/pfizer-nixes-twice-daily-oral-glp-1-candidate-after-high-rates-of-side-effects/" target="_blank" rel="noopener noreferer">Pfizer</a> experiences setbacks; and <a href="https://www.biospace.com/article/ema-requests-more-data-from-glp-1-drugmakers-in-suicidal-ideation-self-harm-probe/" target="_blank" rel="noopener noreferer">European Medicines Agency</a> seeks additional information as part of its ongoing review of the potential risk of suicide and self-harm thoughts associated with the class. Meanwhile, <a href="https://www.biospace.com/article/abbvie-buys-immunogen-in-10b-deal-gains-access-to-adc-for-ovarian-cancer-/" target="_blank" rel="noopener noreferer">AbbVie</a> buys ImmunoGen for a cool $10B and <a href="https://www.biospace.com/article/abbvie-adc-shows-positive-phase-ii-nsclc-data-looks-to-accelerated-approval/" target="_blank" rel="noopener noreferer">scores a win with Teliso-V</a> as <a href="https://www.biospace.com/article/adc-and-glp-1-mania-continue-as-2023-comes-to-close/" target="_blank" rel="noopener noreferer">ADC momentum</a> continues to build. 
Plus, the <a href="https://www.biospace.com/article/fda-launches-probe-of-malignancies-linked-to-car-t-therapies-/" target="_blank" rel="noopener noreferer">FDA</a> investigates malignacies linked to CAR-T.
BioSpace&#39;s Lori Ellis, Greg Slabodkin and Tyler Patchen discuss.

Integrating AI in life sciences to change employee behavior with Microsoft and IQVIA

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.